| |
That was an interesting article on Warfarin, Randy. Ivax though does not claim to have a generic version of Paclitaxel and so will not be subject to the rigors of FDA generic examination. I believe IVX/NPRO was clever in reformulating Taxol into a new drug. This will also help in a defense against an injunction because the FDA will have rated Paxene a different drug, not generic. The Taxol in Paclitaxel, as I have already noted previously, is still under patent by Hauser and will be for some time.
I believe that politically, Paxene and other taxol drugs which might compete with Taxol/Paclitaxel will be easily approved because of the apparent effectiveness, the size and diversity of the recipient population, and the desire to reduce health care costs.
I noticed that short interest in IVX was up 5.5% to 4,540,302 shares or ~10 days to cover at 446,086 avg. daily vol. (WSJ). This seems like an excessive amount. Might we be due for a bounce here? I have been asking myself that since about $9/sh.
Jackson |
|
